Innovative drug BD deals continue to flourish; biotech concept stocks extend strong momentum! CSOP Hang Seng Biotech ETF (03174.HK) surged over 1.3% intraday

NewTimeSpace News: March 26 – Innovative drug concept stocks extended their strong rally today, with Menova Pharmaceutical surging to the daily limit for a third consecutive session (three-board winning streak), while Fushan Pharmaceutical, Baihua Pharmaceutical, Jinkai Biotechnology, Apeloa Pharmaceutical, and WuXi AppTec followed suit with sympathetic gains. CSOP Hang Seng Biotech ETF (03174.HK) jumped over 1.3% at the open.

According to industry statistics, domestic innovative drugmakers sealed 30 BD (Business Development) transactions in January alone, comprising 20 cross-border licensing-out deals with global pharma groups and 10 domestic licensing partnerships. Strikingly, eight of these overseas transactions qualified as blockbusters with total contract values exceeding US$1 billion; the largest single deal reached US$18.5 billion, smashing the historical record for Chinese pharmaceutical out-licensing.

Listed on the Hong Kong Stock Exchange and managed by CSOP Asset Management, CSOP Hang Seng Biotech (03174.HK) tracks the Hang Seng Biotechnology Index. The ETF offers concentrated exposure to Hong Kong-listed biotech leaders across innovative therapeutics, CXO (contract research and manufacturing), vaccines, and gene therapy—a high-beta, high-volatility vehicle suitable for investors seeking tactical allocation to China’s biomedical innovation theme.

Fundamental catalyst: On the evening of March 25, Hengrui Medicine unveiled its 2025 annual results, reporting all-time highs in both top-line and bottom-line metrics. Revenue climbed 13.02% year-on-year to RMB 31.63 billion, while net profit attributable to shareholders rose 21.69% to RMB 7.71 billion. Innovative drug sales expanded 26.09% to RMB 16.34 billion, now representing 58.34% of total drug revenue. Out-licensing revenue contributed an additional RMB 3.39 billion, up 25.62% year-on-year.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.